Home » Stocks » TLC

Taiwan Liposome Company, Ltd. (TLC)

Stock Price: $5.18 USD -0.12 (-2.26%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 229.60M
Revenue (ttm) 3.63M
Net Income (ttm) -34.99M
Shares Out 42.08M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $5.18
Previous Close $5.30
Change ($) -0.12
Change (%) -2.26%
Day's Open 5.21
Day's Range 5.18 - 5.28
Day's Volume 7,209
52-Week Range 4.07 - 12.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Praised as benchmark for small and medium-sized enterprises Praised as benchmark for small and medium-sized enterprises

3 days ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of inhalable liposome ...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targe...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

4 months ago - GlobeNewsWire

On-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses On-schedule completion of enrollment despite COVID-19 pandemic;...

4 months ago - GlobeNewsWire

Patient enrollment of EXCELLENCE pivotal trial reaches 98%

4 months ago - GlobeNewsWire

Technology can be quickly translated and applied to other drugs for direct, extended release delivery to the lungs and is open for collaboration Technology can be quickly translated and applied to other...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to targe...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 14, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

6 months ago - GlobeNewsWire

Dual government support in streamlined development of anti-COVID-19 therapy Dual government support in streamlined development of anti-COVID-19 therapy

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to tar...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to t...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to t...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to t...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 26, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to ta...

8 months ago - GlobeNewsWire

Taiwan Liposome Co. Ltd (NASDAQ: TLC) shares shot higher on Friday after the company announced it was making a regulatory filing for a COVID-19 treatment that has been at the center of some controversy.

8 months ago - 24/7 Wall Street

1% of oral dose for 30-fold lung exposure and reduced cardiotoxicity A cost-effective, easily accessible, user-friendly potential treatment/prevention option

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 05, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targ...

9 months ago - GlobeNewsWire

Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 30, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to ta...

10 months ago - GlobeNewsWire

Taiwan Liposome (NASDAQ: TLC) shares are trading higher on Monday. The company announced the results of its TLCS590 Phase 2 Trial for its Postsurgical pain management demonstrated greater reduction in p...

11 months ago - Benzinga

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target ...

11 months ago - GlobeNewsWire

Subgroup analyses of Phase II data confirm robustness of TLC599’s efficacy response of greater pain reductions than placebo through 24 weeks Subgroup analyses of Phase II data confirm robustness of TLC5...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targe...

11 months ago - GlobeNewsWire

TLC is the only listed biotech company to achieve the elite status every year TLC is the only listed biotech company to achieve the elite status every year

1 year ago - GlobeNewsWire

Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020 Topline results on the analgesic efficacy of TLC590 for po...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan , Jan. 08, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targe...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 27, 2019 (GLOBE NEWSWIRE) --  – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines t...

1 year ago - GlobeNewsWire

Taiwan Liposome has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 24, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to ta...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to targ...

1 year ago - GlobeNewsWire

TLC590 showed faster and longer lasting pain relief than ropivacaine TLC590 showed faster and longer lasting pain relief than ropivacaine

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and com...

1 year ago - GlobeNewsWire

MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in osteoarthritis of the knee MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in o...

1 year ago - GlobeNewsWire

- Phase II results showed statistically significant pain relief through 24 weeks - Phase III to evaluate efficacy of single and repeated doses up to 52 weeks

1 year ago - GlobeNewsWire

TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, re...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in th...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two upcoming inve...

1 year ago - GlobeNewsWire

About TLC

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the pot... [Read more...]

Industry
Biotechnology
IPO Date
Nov 21, 2018
CEO
Jilong Hong
Country
Taiwan
Stock Exchange
NASDAQ
Ticker Symbol
TLC
Full Company Profile

Financial Performance

In 2020, TLC's revenue was 101.93 million, a decrease of -51.26% compared to the previous year's 209.14 million. Losses were -983.31 million, 21.8% more than in 2019.

Financial numbers in millions TWD.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TLC stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 131.66% from the latest price.

Price Target
$12.00
(131.66% upside)
Analyst Consensus: Buy